Short-term clinical and serological follow-up with conventional and conformational anti-desmoglein antibodies in treatment-naïve and previously treated patients with pemphigus vulgaris after receiving rituximab

• Main Authors: Hoorieh Alaeen, MD (Author), Roja Toosi, MD, MPH (Author), Hamidreza Mahmoudi, MD (Author), Kamran Balighi, MD (Author), Soheil Tavakolpour, MS (Author), Amir Teimoupour, PhD (Author), Maryam Daneshpazhooh, MD (Author)
• Formato: Livro
• Publicado em: Wolters Kluwer, 2019-12-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Background: Pemphigus vulgaris (PV) is a blistering, life-threatening autoimmune disease. Ethylenediaminetetraacetic acid (EDTA)-treated desmoglein (Dsg) enzyme-linked immunosorbent assay (ELISA) has recently been suggested to detect nonpathogenic antibodies. Rituximab (RTX) is now considered a firs...